Human Testing of Johnson & Johnson Coronavirus Vaccine to Begin By September. Johnson & Johnson said Monday that its experimental vaccine could be available for emergency use authorization by early 2021. The company said it has committed more than $1 billion to co-fund the vaccine research. with the federal Biomedical Advanced Research and Development Authority, part of the Department of Health and Human Services. Shares of Johnson & Johnson rose more than 4% in premarket trading following the announcement. Johnson & Johnson is also increasing its manufacturing capacity with a new location in the U.S.. and expansions to existing sites in other countries to potentially distribute the vaccine quickly. We have very good early indicators that not only can we depend on this to be a safe vaccine base but also one that will ultimately be effective, Alex Gorsky, Johnson & Johnson CEO, via CNBC. This is a bit of a moonshot for J&J going forward, but it’s one we feel is very, very important for use to be doing at this period in time, Alex Gorsky, via CNBC